Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine for seropositive myasthenia gravis
2024-517083-32-00Phase 2Authorised
- Sponsor
- Medical University of Lublin
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cladribine in myasthenia gravis (MG) (2 arms), sponsored by Medical University of Lublin. Primary endpoint: Change in MG-ADL score. Planned start Oct 2024; status: authorised.
02
Drugs
cladribine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-517083-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517083-32-00.